American Assets Inc. Has $1.14 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• American Assets Inc. increased its holdings in Regeneron Pharmaceuticals by 200% in Q1, now owning 1,800 shares valued at approximately $1,142,000.
• Regeneron reported $12.89 EPS for the last quarter, significantly surpassing the expected $8.43, with a revenue increase of 3.6% year-over-year.
• The company announced a quarterly dividend of $0.88 per share, representing a 0.6% yield and a payout ratio of 8.87%.

American Assets Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 200.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,800 shares of the biopharmaceutical company's stock after purchasing an additional 1,200 shares during the period. Regeneron Pharmaceuticals makes up about 0.4% of American Assets Inc.'s holdings, making the stock its 6th largest position. American Assets Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,142,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. LCM Capital Management Inc raised its position in Regeneron Pharmaceuticals by 5.5% during the first quarter. LCM Capital Management Inc now owns 575 shares of the biopharmaceutical company's stock worth $365,000 after acquiring an additional 30 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. American Assets Investment Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $1,903,000. Thoroughbred Financial Services LLC grew its holdings in Regeneron Pharmaceuticals by 14.9% during the 1st quarter. Thoroughbred Financial Services LLC now owns 680 shares of the biopharmaceutical company's stock valued at $431,000 after buying an additional 88 shares during the last quarter. Finally, Empire Life Investments Inc. increased its position in Regeneron Pharmaceuticals by 57.5% during the first quarter. Empire Life Investments Inc. now owns 6,424 shares of the biopharmaceutical company's stock worth $4,074,000 after buying an additional 2,344 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of REGN stock traded up $4.67 during mid-day trading on Thursday, reaching $559.80. The company's stock had a trading volume of 811,220 shares, compared to its average volume of 970,308. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $60.44 billion, a PE ratio of 14.11, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The company's 50 day simple moving average is $535.40 and its 200-day simple moving average is $600.61. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm posted $11.56 earnings per share. The business's quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analyst Ratings Changes

Several analysts have recently issued reports on REGN shares. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Citigroup reiterated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $841.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.